JP2022548943A5 - - Google Patents

Info

Publication number
JP2022548943A5
JP2022548943A5 JP2022517799A JP2022517799A JP2022548943A5 JP 2022548943 A5 JP2022548943 A5 JP 2022548943A5 JP 2022517799 A JP2022517799 A JP 2022517799A JP 2022517799 A JP2022517799 A JP 2022517799A JP 2022548943 A5 JP2022548943 A5 JP 2022548943A5
Authority
JP
Japan
Prior art keywords
cells
derived
cell
car
bcma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052890 external-priority patent/WO2021062281A2/en
Publication of JP2022548943A publication Critical patent/JP2022548943A/ja
Publication of JP2022548943A5 publication Critical patent/JP2022548943A5/ja
Priority to JP2025211240A priority Critical patent/JP2026041849A/ja
Pending legal-status Critical Current

Links

JP2022517799A 2019-09-25 2020-09-25 複数標的化エフェクター細胞およびその使用 Pending JP2022548943A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025211240A JP2026041849A (ja) 2019-09-25 2025-12-01 複数標的化エフェクター細胞およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906046P 2019-09-25 2019-09-25
US62/906,046 2019-09-25
US201962944187P 2019-12-05 2019-12-05
US62/944,187 2019-12-05
PCT/US2020/052890 WO2021062281A2 (en) 2019-09-25 2020-09-25 Multi-targeting effector cells and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025211240A Division JP2026041849A (ja) 2019-09-25 2025-12-01 複数標的化エフェクター細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2022548943A JP2022548943A (ja) 2022-11-22
JP2022548943A5 true JP2022548943A5 (enExample) 2023-10-03

Family

ID=75166460

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517799A Pending JP2022548943A (ja) 2019-09-25 2020-09-25 複数標的化エフェクター細胞およびその使用
JP2025211240A Pending JP2026041849A (ja) 2019-09-25 2025-12-01 複数標的化エフェクター細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025211240A Pending JP2026041849A (ja) 2019-09-25 2025-12-01 複数標的化エフェクター細胞およびその使用

Country Status (11)

Country Link
US (1) US20220378831A1 (enExample)
EP (1) EP4034638A4 (enExample)
JP (2) JP2022548943A (enExample)
KR (1) KR20220085779A (enExample)
CN (1) CN114867846A (enExample)
AU (1) AU2020353166A1 (enExample)
BR (1) BR112022005602A2 (enExample)
CA (1) CA3149585A1 (enExample)
IL (1) IL291484A (enExample)
MX (1) MX2022003414A (enExample)
WO (1) WO2021062281A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP4097220A4 (en) * 2020-01-30 2024-03-20 ImmunityBio, Inc. ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
JP2024522756A (ja) * 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
GB202110363D0 (en) * 2021-07-19 2021-09-01 Celyad S A NKG2D CAR cells expressing IL-18 for adoptive cell therapy
CA3228865A1 (en) * 2021-08-18 2023-02-23 Bahram Valamehr Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody
JP2024539013A (ja) * 2021-10-20 2024-10-28 フェイト セラピューティクス，インコーポレイティド 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
US20250018034A1 (en) * 2021-11-08 2025-01-16 Fate Therapeutics, Inc. Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
WO2024004814A1 (en) * 2022-06-27 2024-01-04 Kyoto University A METHOD FOR PRODUCING iPS CELL -DERIVED NATURAL KILLER CELLS
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
EP4593868A1 (en) * 2022-09-26 2025-08-06 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
CN120092090A (zh) * 2022-11-07 2025-06-03 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
JP2026525671A (ja) * 2023-07-26 2026-07-31 ビーアールエル メディシン （シャンハイ） カンパニー リミテッド 疾患を治療するための方法及び組成物
WO2025109493A1 (en) * 2023-11-21 2025-05-30 National University Of Singapore Chimeric Receptors with Binding Capacity for Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
BR112016024546A2 (pt) * 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
US11905528B2 (en) * 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas

Similar Documents

Publication Publication Date Title
JP2022541441A5 (enExample)
JP2021505131A5 (enExample)
JP2022550899A5 (enExample)
JP2022510207A5 (enExample)
US20260055157A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2021519061A5 (enExample)
JP2023505206A5 (enExample)
JP2023530704A5 (enExample)
JP7783746B2 (ja) 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成
JP2023548467A5 (enExample)
JP2023549098A5 (enExample)
JP2023548829A5 (enExample)
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
JP2025108510A (ja) 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用
JP2023545992A5 (enExample)
JP2022510207A (ja) 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法
JP2021506236A (ja) 強化された免疫エフェクター細胞およびその使用
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
JP2023029624A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
EP3029137B1 (en) Genetic modified pluri- or multipotent stem cells and uses thereof
JP2024533375A5 (enExample)
AU2021338819A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP7701453B2 (ja) 固形腫瘍標的化骨格を有する細胞及びその使用
JP2024515920A5 (enExample)
JP2025105605A5 (enExample)